Detail akcie Shield Therapeutics online

Business Summary: Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Shield Therapeutics PLC revenues increased 77% to $21.4M. Net loss decreased 38% to $9.5M. Revenues reflect USA segment increase of 75% to $19.2M, Canada segment increase from $0K to $420K, Netherlands segment increase of 39% to $1.5M. Lower net loss reflects Feraccru segment loss decrease of 66% to $4.3M, Unallocated segment loss decrease of 9% to $1.5M.